INTRODUCTION
Polycystic ovary syndrome (PCOS) is believed to constitute the most frequently encountered endocrinopathy in women of reproductive age present in 5 – 7% of women of reproductive age [1]. Although the first description of polycystic ovary syndrome (PCOS) is generally credited to Stein and Leventhal in 1935, it may have been observed as early as 1721, when the Italian scientist Antonio Vallisneri observed “young married women, moderately obese and infertile, with two larger than normal ovaries, bumpy and shiny, whitish, just like pigeon eggs.” [2]. This depiction sounds strikingly similar to the subfertility and obesity commonly found in PCOS. It was not until 1921 that Achard noticed a relationship between hyperandrogenism and insulin resistance in their study of the “bearded diabetic woman.” And in 1935, Stein and Leventhal made the connection between amenorrhea and polycystic ovaries. In addition, they also noticed the occurrence of masculinizing changes, such as hirsutism and acne, in many patients with polycystic ovaries [3].

Diagnosis of PCOS is made according to Rotterdam criteria in presence of at least two of the following: 1) oligomenorrhea and/or anovulation; 2) hyperandrogenism (clinical and/or biochemical); 3) polycystic ovaries with the exclusion of other etiologies. Women with PCOS demonstrate marked clinical heterogeneity; the commonly associated features of hirsutism, acne, polycystic-appearing ovaries, obesity and acanthosis nigricans are neither uniform nor universal [1]. Since its description in 1935 by Stein and Leventhal [3], much has been learned about the pathophysiology of PCOS from its neuroendocrine underpinnings [4] to an ever-growing understanding of the link between obesity, insulin resistance (IR) and PCOS [5]. In time the disorder may lead to onset of hyperinsulinemia, insulin resistance, gestational diabetes, early onset of type 2 diabetes mellitus (DM), dyslipidemia and cardiovascular disease (CVD) [1]. Hence, this study is undertaken to know the blood glucose levels in PCOS subjects.

MATERIALS AND METHODS
The study was undertaken in Hassan Institute of Medical Sciences Hassan. It is a cross sectional study. The subjects for the study were selected from the outpatient department of obstetrics and gynaecology. The women between 15-25 years who were fulfilling the criteria for PCOS were considered as cases. Age and anthropometrically matched women...
with normal menstrual cycles were selected as controls. In both groups 50 subjects were selected. Women with disorders like pre-existing diabetes, hypertension, thyroid abnormalities or other ovarian or uterine problems were excluded from the study. For this study the ethical committee permission was taken. Informed consent was taken from all the subjects. After obtaining a detailed history of all subjects the height and weight of the subjects were measured to calculate body mass index (BMI). The vital parameters like pulse and blood pressure were measured and ultrasonography of abdomen and pelvis was done to look for polycystic ovaries. Women fulfilling the criteria for PCOS were taken as cases. Women in both groups were advised to come empty stomach in the morning after overnight fasting. In the early morning under aseptic precaution 2ml of venous blood was taken for estimation of fasting blood sugar (FBS) level, this was followed by oral glucose tolerance test (OGTT), by giving 75gm of glucose with 300ml of water. After 2 hours once again 2ml of venous blood was taken under aseptic precaution for estimation of post prandial blood sugar level (PPBS). The results were expressed in terms of mean ± SD. The test of significance used was student ‘t’ test and a p value less than 0.05 was considered statistically significant.

RESULTS

The study included 100 subjects, 50 cases and 50 controls. Table 1 shows the basic anthropometric parameters of both groups and there is no statistically significant difference of BMI between two groups. The table 2 shows the value of FBS and PPBS in cases and controls. The results of our study shows raised levels of FBS and PPBS in women with PCOS compared to controls.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cases Mean ± SD</th>
<th>Controls Mean ± SD</th>
<th>‘t’-value</th>
<th>‘P’ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>20.02± 0.55</td>
<td>19.38± 0.53</td>
<td>0.131</td>
<td>&gt; 0.05*</td>
</tr>
<tr>
<td>BMI (kg/M^2)</td>
<td>22.36± 0.73</td>
<td>22.43± 0.62</td>
<td>0.123</td>
<td>&gt; 0.05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group (Mean ± SD)</th>
<th>Mean difference</th>
<th>95% CI of difference</th>
<th>t-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS</td>
<td>Study 92.11 ± 5.21</td>
<td>Control 87.16 ± 5.57</td>
<td>4.95</td>
<td>2.8 – 7.09</td>
<td>4.58</td>
</tr>
<tr>
<td>PPBS</td>
<td>Study 129.15 ± 7.6</td>
<td>Control 120.11 ± 8.23</td>
<td>9.04</td>
<td>5.89 – 12.18</td>
<td>5.7</td>
</tr>
</tbody>
</table>

Fig-1: Comparison of FBS between study and control group
DISCUSSION

In this study we evaluated the level of FBS and PPBS (2hrs after OGGT) in PCOS and compared the values with controls, and it clearly indicated that both the values are greater in PCOS and which was statistically significant. The results of our study are consistent with finding of Amruta Bennal et al [6], Farah Deeba et al [7], Jie Ping Jie et al [8], Richaard S Largo et al [9].

PCOS is a syndrome of ovarian dysfunction that is characterized by anovulation, hyperandrogenism, and/or the presence of polycystic ovary morphology[10]. Furthermore, PCOS is also associated with insulin resistance, pancreatic β-cell dysfunction, and obesity, abnormalities that confer a substantially increased risk for metabolic syndrome and type 2 diabetes mellitus[11]. They are also at increased risk for atherosclerotic cardiovascular disease (CVD) due to increased prevalence of obesity and central adiposity as well as to hypertension, hyperinsulinemia, type 2 DM, and dyslipidemia in these patients[12].

Although much remains unknown regarding the underlying pathophysiology of PCOS, a form of insulin resistance intrinsic to the syndrome appears to play a central role in its development. Among many women with PCOS, the observed insulin resistance is partially explained by excess adiposity; however, many studies have shown that even lean women with PCOS have increased insulin resistance compared with normal controls, as shown in our study. Although the nature of insulin resistance in PCOS is currently unclear, defects in insulin receptor or post-receptor signal transduction, altered adipocyte lipolysis, decreased glucose transporter 4 in adipocytes, and impaired release of a D-chiro-inositol mediator have all been implicated. Furthermore, many women with PCOS exhibit β-cell dysfunction, rendering insulin response to a glucose load insufficient for the degree of insulin resistance in PCOS [13].

Hence women with PCOS irrespective of their BMI are at increased risk of developing glucose intolerance and type 2 diabetes mellitus, hence they have to be screened periodically with OGGT so as to detect diabetes mellitus and start treatment early. By this we can prevent the complication arising out of it. PCOS women should also be advised for life style modification and exercise. Androgen Excess Society of Virginia, prescribes, Patients with normal glucose tolerance should be rescreened at least once every 2 year, or more frequently if additional risk factors are identified. Those with IGT should be screened annually for development of type 2 Diabetes Mellitus [13].

CONCLUSION

Periodic screening of PCOS patients should be carried out as they are more prone to develop glucose intolerance and diabetes mellitus and failing to do so the patient may end up in cardiovascular and other complication.

REFERENCES
10. Azziz R; Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. The Journal of Clinical Endocrinology & Metabolism, 2006; 91(3):781-785.
12. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS; Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clinical Endocrinology (Oxf), 1992; 37: